This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piscitelli, S. C.
Right arrow Articles by Polis, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piscitelli, S. C.
Right arrow Articles by Polis, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 647-650, Vol. 43, No. 3
0066-4804/99

A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients

Stephen C. Piscitelli,1,* Grace Kelly,2 Robert E. Walker,2 Joseph Kovacs,2 Judith Falloon,2 Richard T. Davey Jr.,2 Sangita Raje,3 Henry Masur,4 and Michael A. Polis2

Departments of Pharmacy1 and Critical Care Medicine,4 Clinical Center, and Laboratory of Immunoregulation,2 National Institute of Allergy and Infectious Diseases, and Clinical Pharmacokinetics Section, National Cancer Institute,3 National Institutes of Health, Bethesda, Maryland

Received 25 February 1998/Returned for modification 19 September 1998/Accepted 7 December 1998

The effects of multiple opportunistic infection medications on stavudine pharmacokinetics were evaluated. Ten patients with CD4 counts of less than 200 cells/mm3 received stavudine (40 mg twice daily) in combination with one to three other drugs used to treat opportunistic infections. Serial blood samples for stavudine concentrations were collected after 1 week of therapy on each regimen and assayed for stavudine by using a validated high-pressure liquid chromatography method. Although the maximum concentration of drug in serum was significantly decreased when the drug was given in combination with three opportunistic infection medications, the area under the concentration-time curve did not significantly differ across various treatment regimens. Stavudine exposure was not significantly altered by multiple concomitant medications. Side effects were minor throughout the 3-month study period. The tolerability of stavudine, combined with its lack of drug interactions, makes it an attractive agent for use as part of a combination regimen.

* Corresponding author. Mailing address: Clinical Center Pharmacy Department, National Institutes of Health, Bldg. 10, Room 1N257, Bethesda, MD 20892-1196. Phone: (301) 496-2997. Fax: (301) 496-0210. E-mail: spisc{at}nih.gov.

Antimicrobial Agents and Chemotherapy, March 1999, p. 647-650, Vol. 43, No. 3
0066-4804/99


This article has been cited by other articles:

  • Jordan, M. K., Polis, M. A., Kelly, G., Narang, P. K., Masur, H., Piscitelli, S. C. (2000). Effects of Fluconazole and Clarithromycin on Rifabutin and 25-O-Desacetylrifabutin Pharmacokinetics. Antimicrob. Agents Chemother. 44: 2170-2172 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»